EP2361933A3 - Anticorps contre l'interleukine-1 bêta - Google Patents

Anticorps contre l'interleukine-1 bêta Download PDF

Info

Publication number: EP2361933A3
Authority: EP; European Patent Office
Prior art keywords: antigen; beta; light chain; antibodies against; immunoglobulin molecules
Prior art date: 2005-01-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP10183582A

Other languages

German (de)

English (en)

Other versions

EP2361933A2 (fr

Inventor

Larry Green

Raffaella Faggioni

Orit Foord

Scott L. Klakamp

Giorgio Senaldi

Amy K. Schneider

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen Fremont Inc

Original Assignee

Amgen Fremont Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-26

Filing date

2006-01-19

Publication date

2012-05-02

2006-01-19 Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc

2011-08-31 Publication of EP2361933A2 publication Critical patent/EP2361933A2/fr

2012-05-02 Publication of EP2361933A3 publication Critical patent/EP2361933A3/fr

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP10183582A 2005-01-26 2006-01-19 Anticorps contre l'interleukine-1 bêta Withdrawn EP2361933A3 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64764305P	2005-01-26	2005-01-26
US75380005P	2005-12-22	2005-12-22
EP06718993A EP1851245B1 (fr)	2005-01-26	2006-01-19	Anticorps dirigés contre l'interleukine-1 beta

Related Parent Applications (3)

Application Number	Title	Priority Date	Filing Date
EP06718993.6 Division		2006-01-19
WOPCT/US2006/002011 Previously-Filed-Application		2006-01-19
EP06718993A Division-Into EP1851245B1 (fr)	2005-01-26	2006-01-19	Anticorps dirigés contre l'interleukine-1 beta

Publications (2)

Publication Number	Publication Date
EP2361933A2 EP2361933A2 (fr)	2011-08-31
EP2361933A3 true EP2361933A3 (fr)	2012-05-02

Family

ID=36740960

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP10183582A Withdrawn EP2361933A3 (fr)	2005-01-26	2006-01-19	Anticorps contre l'interleukine-1 bêta
EP06718993A Expired - Lifetime EP1851245B1 (fr)	2005-01-26	2006-01-19	Anticorps dirigés contre l'interleukine-1 beta

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP06718993A Expired - Lifetime EP1851245B1 (fr)	2005-01-26	2006-01-19	Anticorps dirigés contre l'interleukine-1 beta

Country Status (8)

Country	Link
US (2)	US7566772B2 (fr)
EP (2)	EP2361933A3 (fr)
AR (1)	AR052889A1 (fr)
AU (1)	AU2006208286A1 (fr)
CA (1)	CA2590164A1 (fr)
ES (1)	ES2395953T3 (fr)
TW (1)	TW200637873A (fr)
WO (1)	WO2006081139A2 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA05014155A (es) *	2003-06-27	2006-05-25	Abgenix Inc	Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
ES2335232T3 (es)	2005-06-21	2010-03-23	Xoma Technology Ltd.	Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
CL2007002668A1 (es)	2006-09-20	2008-05-09	Amgen Inc	Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
WO2008077145A2 (fr)	2006-12-20	2008-06-26	Xoma Technology Ltd.	Procédés de traitement de maladies associées à il-1β
WO2008145664A1 (fr) *	2007-05-29	2008-12-04	Novartis Ag	Nouvelles indications pour une thérapie anti-il-i-bêta
AU2008329518A1 (en) *	2007-11-27	2009-06-04	Viventia Biotechnologies Inc.	Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
RU2018100129A (ru)	2007-12-20	2019-02-20	Ксома (Сша) Ллс	Способы лечения подагры
EP2282769A4 (fr) *	2008-04-29	2012-04-25	Abbott Lab	Immunoglobulines à double domaine variable et utilisations
EP2297209A4 (fr)	2008-06-03	2012-08-01	Abbott Lab	Immunoglobulines à deux domaines variables et leurs utilisations
KR20110016959A (ko)	2008-06-03	2011-02-18	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
US8822645B2 (en)	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AU2009289547A1 (en)	2008-09-05	2010-03-11	Xoma (Us) Llc	Methods for treating or preventing IL-1beta related diseases
SG2014014534A (en) *	2009-05-29	2014-07-30	Xoma Technology Ltd	CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
MX2012002651A (es) *	2009-09-01	2012-05-22	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
AU2010298036B2 (en)	2009-09-25	2015-05-21	Xoma Technology Ltd.	Screening methods
AR078651A1 (es) *	2009-10-15	2011-11-23	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
PT2542257T (pt)	2010-03-01	2017-10-09	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
BR112012028557A2 (pt)	2010-05-07	2019-09-24	Xoma Technology Ltd.	uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
KR20130100118A (ko)	2010-08-03	2013-09-09	아비에 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en)	2010-08-26	2015-06-02	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2012034039A2 (fr) *	2010-09-10	2012-03-15	Apexigen, Inc.	Anticorps anti-il-1 bêta et leurs procédés d'utilisation
CN104144946A (zh)	2011-12-19	2014-11-12	爱克索马美国有限责任公司	治疗痤疮的方法
AR089529A1 (es)	2011-12-30	2014-08-27	Abbvie Inc	Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
SG10201708562VA (en) *	2012-02-13	2017-12-28	Agency Science Tech & Res	IL-1β Neutralizing Human Monoclonal Antibodies
PE20151179A1 (es)	2012-11-01	2015-09-12	Abbvie Inc	Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
MX374817B (es) *	2012-11-05	2025-03-06	Delenex Therapeutics Ag	Miembros de union para il-1 beta.
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
ES2895848T3 (es)	2012-12-17	2022-02-22	Cell Medica Inc	Anticuerpos contra IL-1 beta
KR20150136061A (ko)	2013-02-01	2015-12-04	산타 마리아 바이오테라퓨틱스, 인코포레이티드	대상에 항-액티빈-a 화합물의 투여
AU2014227732A1 (en)	2013-03-15	2015-09-17	Abbvie Inc.	Dual specific binding proteins directed against IL-1 beta and IL-17
WO2014144817A2 (fr)	2013-03-15	2014-09-18	Amgen Inc.	Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
EP3712166A1 (fr)	2013-09-05	2020-09-23	Amgen Inc.	Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
CA2943857C (fr)	2014-03-31	2023-07-11	Universitetet I Tromso - Norges Arktiske Universitet	Anticorps anti-hpa-1a
WO2015175861A1 (fr)	2014-05-16	2015-11-19	Amgen Inc.	Dosage pour la détection de populations de cellules th1 et th2
WO2016073853A1 (fr)	2014-11-06	2016-05-12	Scholar Rock, Inc.	Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
EP3307779A2 (fr) *	2015-06-12	2018-04-18	Alector LLC	Anticorps anti-cd33 et leurs procédés d'utilisation
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MY188405A (en)	2015-08-05	2021-12-08	Janssen Biotech Inc	Anti-cd154 antibodies and methods of using them
EA038146B1 (ru)	2015-09-15	2021-07-13	Сколар Рок, Инк.	Антитела к про-/латентному миостатину и их применения
PE20181367A1 (es) *	2015-09-30	2018-08-27	Janssen Biotech Inc	Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
CN115814077A (zh)	2016-01-08	2023-03-21	供石公司	抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl)	2016-06-13	2026-05-25	Scholar Rock, Inc.	Stosowanie inhibitorów miostatyny i terapii skojarzonych
SG10201606949QA (en)	2016-08-19	2018-03-28	Singapore Health Serv Pte Ltd	Immunosuppressive composition for use in treating immunological disorders
HRP20230308T1 (hr)	2017-01-06	2023-05-12	Scholar Rock, Inc.	Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
CN106928354B (zh) *	2017-04-25	2020-07-17	长春金赛药业有限责任公司	抗IL-1β单克隆抗体及其应用
MY205541A (en)	2017-08-03	2024-10-25	Alector Llc	Anti-cd33 antibodies and methods of use thereof
US12325737B2 (en)	2018-03-26	2025-06-10	Amgen Inc.	Total afucosylated glycoforms of antibodies produced in cell culture
AR119259A1 (es)	2018-08-31	2021-12-09	Alector Llc	Anticuerpos anti-cd33 y métodos de uso de los mismos
US11976115B2 (en) *	2018-11-07	2024-05-07	Zeda Biopharmaceuticals, Inc.	Antibody binding to human IL-1β, preparation method therefor and use thereof
CN117343173A (zh) *	2019-03-07	2024-01-05	瑞阳(苏州)生物科技有限公司	人IL-1β蛋白结合分子及其编码基因和应用
KR102087743B1 (ko) *	2019-06-10	2020-03-12	을지대학교 산학협력단	IL-1beta에 특이적으로 결합하는 항체 및 그의 용도
KR20220069982A (ko)	2019-09-26	2022-05-27	암젠 인크	항체 조성물의 생산 방법
EP4045515A4 (fr)	2019-10-18	2023-10-18	The Regents Of The University Of Michigan	Systèmes de capteurs pour biomatériaux
MX2022005983A (es)	2019-11-18	2022-09-07	Janssen Biotech Inc	Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
BR112022021780A2 (pt) *	2020-04-27	2023-03-07	Twist Bioscience Corp	Bibliotecas de ácido nucléico variantes para coronavírus
WO2021247892A1 (fr)	2020-06-04	2021-12-09	Amgen Inc.	Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
US20240043501A1 (en)	2020-10-15	2024-02-08	Amgen Inc.	Relative unpaired glycans in antibody production methods
CA3201637A1 (fr)	2020-11-18	2022-05-27	Novartis Ag	Anticorps bispecifiques destines a etre utilises dans le traitement de l'inflammasomapathie nlrc4-gof
WO2022150809A1 (fr) *	2021-01-05	2022-07-14	Immunome, Inc.	Cocktail d'anticorps contre la protéine de spicule de sars-cov-2
AU2022289365A1 (en)	2021-06-07	2023-12-14	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja)	2021-10-05	2024-10-10	アムジエン・インコーポレーテツド	Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (fr)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions et méthodes pour l'immunothérapie cellulaire
CN114989299B (zh) *	2022-06-21	2023-05-26	北京索莱宝科技有限公司	一种单克隆抗体的组合物及其应用、检测人白细胞介素1β的试剂、试剂盒和方法
TW202428605A (zh) *	2022-10-31	2024-07-16	美商安進公司	抗體表徵方法
CN120677175A (zh)	2022-12-22	2025-09-19	供石公司	肌生成抑制蛋白活化的选择性和强效抑制剂
JP2026516670A (ja)	2023-04-20	2026-05-26	アムジエン・インコーポレーテツド	相対的な不対グリカン含有量を決定する方法
AU2024325342A1 (en)	2023-08-14	2026-02-26	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (fr)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions et méthodes pour l'immunothérapie cellulaire
WO2026064353A1 (fr) *	2024-09-17	2026-03-26	The Board Of Regents Of The University Of Texas System	Agents diagnostics et thérapeutiques ciblant slc13a3
WO2026090253A1 (fr)	2024-10-23	2026-04-30	Amgen Inc.	Procédés de détermination de la teneur en appariement de glycanes
WO2026145640A1 (fr) *	2025-01-03	2026-07-09	长春金赛药业有限责任公司	COMPOSITION PHARMACEUTIQUE D'ANTICORPS ANTI-IL1β ET SON UTILISATION

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001053353A2 (fr) *	2000-01-21	2001-07-26	Novartis Ag	Anticorps anti-interleukine 1$g(b) humain
WO2002016436A2 (fr) *	2000-08-22	2002-02-28	Novartis Ag	ANTICORPS DE LA IL-1β HUMAINE
WO2003010282A2 (fr) *	2001-07-26	2003-02-06	Eli Lilly And Company	Anticorps vis-a-vis de l'interleukine 1 beta (il-1$g(b))
US20030026806A1 (en) *	2000-10-27	2003-02-06	Amgen Inc.	Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2004067568A2 (fr) *	2003-01-24	2004-08-12	Applied Molecular Evolution, Inc	Antagonistes de l'il-1 beta humaine
WO2004072116A2 (fr) *	2003-02-13	2004-08-26	Celltech R & D Limited	Molecules d'anticorps possedant une specificite pour il-1? humain

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3180193A (en)	1963-02-25	1965-04-27	Benedict David	Machines for cutting lengths of strip material
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
EP0088046B1 (fr)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipides en phase aqueuse
JPS58166633A (ja)	1982-03-29	1983-10-01	Toshiba Corp	有機溶媒電池用正極
JPS58166634A (ja)	1982-03-29	1983-10-01	Toshiba Corp	有機溶媒電池用正極
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (fr)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipides et composés tensio-actifs en phase aqueuse
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de)	1983-09-26	1997-12-11	Udo Dr Med Ehrenfeld	Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (fr)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Composition pharmaceutique contenant de l'urokinase
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
EP0569687B1 (fr)	1984-05-18	2002-08-21	New England Medical Center Hospitals, Inc.	Séquences de cADN de l'IL-1 humaine codant pour des protéines biologiquement actives de l'IL-1 humaine
US5484887A (en)	1984-06-19	1996-01-16	Immunex Corporation	Homogeneous interleukin 1
JPS62170639A (ja)	1986-01-22	1987-07-27	株式会社システムメンテナンス	防蟻板の取付け工法
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4935343A (en)	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
DK590387A (da)	1986-11-13	1988-05-14	Otsuka Pharma Co Ltd	Antistoffer mod interleukin-1
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
FR2615622B1 (fr)	1987-05-19	1994-05-06	Ire Medgenix Sa	Dosage plasmatique de monokines
KR0148009B1 (ko)	1988-05-27	1998-08-01	그래고리 비. 아보트	인터루킨-1 억제제
JP2554528B2 (ja)	1988-09-19	1996-11-13	大塚製薬株式会社	副腎皮質刺激ホルモン分泌能検査薬
DE68925935T2 (de)	1988-10-01	1996-08-14	Otsuka Pharma Co Ltd	Antikörper gegen Interleukin-1-beta
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2640146B1 (fr)	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
ATE147634T1 (de)	1988-12-19	1997-02-15	American Cyanamid Co	Produkte zur behandlung des endotoxin -schocks bei einem säugetier
EP1690935A3 (fr)	1990-01-12	2008-07-30	Abgenix, Inc.	Génération d'anticorps xenogéniques
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr)	1990-06-29	1992-01-03	Thomson Csf	Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2090473A1 (fr)	1990-08-29	1992-03-01	Robert M. Kay	Recombinaison homologue dans des cellules mammaliennes
WO1992010210A1 (fr)	1990-12-14	1992-06-25	E.I. Du Pont De Nemours And Company	Inhibition de l'angiogenese par il-1
WO1992022670A1 (fr)	1991-06-12	1992-12-23	Genpharm International, Inc.	Detection precoce d'embryons transgeniques
AU2235992A (en)	1991-06-14	1993-01-12	Genpharm International, Inc.	Transgenic immunodeficient non-human animals
EP0591420A1 (fr)	1991-06-28	1994-04-13	New England Deaconess Hospital	Lignee de megacaryocytes differencies produisant de nouveaux facteurs de differenciation de megacaryocytes
WO1993004169A1 (fr)	1991-08-20	1993-03-04	Genpharm International, Inc.	Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
TW318189B (fr)	1991-12-06	1997-10-21	American Cyanamid Co
JPH07503132A (ja)	1991-12-17	1995-04-06	ジェンファーム　インターナショナル，インコーポレイティド	異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994000569A1 (fr)	1992-06-18	1994-01-06	Genpharm International, Inc.	Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
US5981175A (en)	1993-01-07	1999-11-09	Genpharm Internation, Inc.	Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en)	1993-04-26	1994-11-21	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5985838A (en) *	1993-04-29	1999-11-16	Vertex Pharmaceuticals, Inc.	Peptide analogs as irreversible interleukin-1β protease inhibitors
WO1995001997A1 (fr)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
WO1996034096A1 (fr)	1995-04-28	1996-10-31	Abgenix, Inc.	Anticorps humains derives de xeno-souris immunisees
US5686246A (en)	1995-08-03	1997-11-11	Kornman; Kenneth S.	Detecting genetic predisposition to periodontal disease
GB9517538D0 (en)	1995-08-26	1995-10-25	Therapeutic Antibodies Inc	Production and therapeutic combinations, of antibodies
EP0773288A3 (fr)	1995-08-29	1997-07-09	Kirin Brewery	Animal chimérique et méthode de production
US6406710B1 (en)	1996-01-16	2002-06-18	Nikos Panayotatos	Protein occlusion for delivery of small molecules
EP1972194A1 (fr)	1996-12-03	2008-09-24	Amgen Fremont Inc.	Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6407218B1 (en)	1997-11-10	2002-06-18	Cytimmune Sciences, Inc.	Method and compositions for enhancing immune response and for the production of in vitro mabs
JP2002511259A (ja) *	1998-04-09	2002-04-16	ジェンセット	５’ｅｓｔおよびコードされるヒトタンパク質
US6251598B1 (en)	1998-10-30	2001-06-26	Interleukin Genetics, Inc.	Methods for diagnosing sepsis
AU778975B2 (en)	1999-02-10	2004-12-23	Interleukin Genetics, Inc.	Therapeutics and diagnostics based on an IL-1B mutation
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PE20020132A1 (es)	2000-06-29	2002-03-04	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
ES2645563T3 (es)	2001-11-30	2017-12-05	Amgen Fremont Inc.	Animales transgénicos que portan genes de cadena ligera de Ig humana
GB0312481D0 (en) *	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
JP6071725B2 (ja)	2013-04-23	2017-02-01	カルソニックカンセイ株式会社	電気自動車の駆動力制御装置
US11284893B2 (en)	2019-04-02	2022-03-29	Covidien Lp	Stapling device with articulating tool assembly

2006
- 2006-01-19 EP EP10183582A patent/EP2361933A3/fr not_active Withdrawn
- 2006-01-19 AU AU2006208286A patent/AU2006208286A1/en not_active Abandoned
- 2006-01-19 EP EP06718993A patent/EP1851245B1/fr not_active Expired - Lifetime
- 2006-01-19 CA CA002590164A patent/CA2590164A1/fr not_active Abandoned
- 2006-01-19 ES ES06718993T patent/ES2395953T3/es not_active Expired - Lifetime
- 2006-01-19 US US11/335,907 patent/US7566772B2/en not_active Expired - Fee Related
- 2006-01-19 WO PCT/US2006/002011 patent/WO2006081139A2/fr not_active Ceased
- 2006-01-25 AR ARP060100271A patent/AR052889A1/es unknown
- 2006-01-26 TW TW095103137A patent/TW200637873A/zh unknown
2009
- 2009-06-19 US US12/456,660 patent/US7964193B2/en not_active Expired - Fee Related

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001053353A2 (fr) *	2000-01-21	2001-07-26	Novartis Ag	Anticorps anti-interleukine 1$g(b) humain
WO2002016436A2 (fr) *	2000-08-22	2002-02-28	Novartis Ag	ANTICORPS DE LA IL-1β HUMAINE
US20030026806A1 (en) *	2000-10-27	2003-02-06	Amgen Inc.	Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2003010282A2 (fr) *	2001-07-26	2003-02-06	Eli Lilly And Company	Anticorps vis-a-vis de l'interleukine 1 beta (il-1$g(b))
WO2004067568A2 (fr) *	2003-01-24	2004-08-12	Applied Molecular Evolution, Inc	Antagonistes de l'il-1 beta humaine
WO2004072116A2 (fr) *	2003-02-13	2004-08-26	Celltech R & D Limited	Molecules d'anticorps possedant une specificite pour il-1? humain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BODER ERIC T ET AL: "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 20, 26 September 2000 (2000-09-26), pages 10701 - 10705, XP002185398, ISSN: 0027-8424 *
GREEN L L: "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 11 - 23, XP004187631, ISSN: 0022-1759 *
JACKSON J R ET AL: "In Vitro Antibody Maturation Improvement of a High Affinity, Neutralizing Antibody Against IL-1Beta", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, no. 7, 1 April 1995 (1995-04-01), pages 3310 - 3319, XP000941315, ISSN: 0022-1767 *

Also Published As

Publication number	Publication date
US20070065439A1 (en)	2007-03-22
ES2395953T3 (es)	2013-02-18
US7566772B2 (en)	2009-07-28
AU2006208286A1 (en)	2006-08-03
EP1851245B1 (fr)	2012-10-10
WO2006081139A3 (fr)	2007-02-15
AR052889A1 (es)	2007-04-11
TW200637873A (en)	2006-11-01
US7964193B2 (en)	2011-06-21
EP2361933A2 (fr)	2011-08-31
WO2006081139A2 (fr)	2006-08-03
CA2590164A1 (fr)	2006-08-03
EP1851245A2 (fr)	2007-11-07
EP1851245A4 (fr)	2008-05-14
US20100183616A1 (en)	2010-07-22

Legal Events

Date	Code	Title	Description
2011-07-29	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-08-31	17P	Request for examination filed	Effective date: 20101015
2011-08-31	AC	Divisional application: reference to earlier application	Ref document number: 1851245 Country of ref document: EP Kind code of ref document: P
2011-08-31	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2012-03-30	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2012-05-02	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2012-05-02	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/00 20060101AFI20120327BHEP Ipc: A61K 39/00 20060101ALI20120327BHEP Ipc: A61K 39/395 20060101ALI20120327BHEP
2012-10-31	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AMGEN FREMONT INC.
2013-03-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2013-05-01	18D	Application deemed to be withdrawn	Effective date: 20121103

Publication	Publication Date	Title
WO2006081139A3 (fr)	2007-02-15	Anticorps diriges contre interleukine-1 beta
WO2006130458A3 (fr)	2007-02-08	Anticorps diriges contre cd20 et leurs utilisations
TW200634027A (en)	2006-10-01	Antibodies directed to angiopoietin-2 and uses thereof
WO2007120693A3 (fr)	2008-05-29	AGENTS DE LIAISON CIBLÉS, DIRIGÉS CONTRE L'uPAR, ET UTILISATIONS
WO2005118635A3 (fr)	2006-06-15	Anticorps anti-cd3 et leurs methodes d'utilisation
WO2004050683A8 (fr)	2005-07-28	Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
WO2008112004A3 (fr)	2009-04-02	ANTICORPS DIRIGÉS CONTRE αVβ6 ET LEURS UTILISATIONS
WO2003057857A3 (fr)	2006-09-28	Anticorps diriges contre les pdgfd et utilisations
WO2007109307A3 (fr)	2008-10-30	Anticorps dirigés contre la protéine 4 du type angiopoïétine et utilisations de ceux-ci
WO2004050850A3 (fr)	2006-03-09	Anticorps diriges contre la phospholipase a2 et utilisations
WO2006052591A3 (fr)	2006-10-05	Anticorps anti-properdine et procédé de fabrication et d'utilisation de ceux-ci
WO2004016769A3 (fr)	2004-10-14	Anticorps diriges contre la proteine chimioattractive monocytaire 1 (mcp-1) et leurs utilisations
WO2006104978A3 (fr)	2006-12-14	Anticorps dirigés contre les antigènes majeurs de la ténascine
WO2004084823A3 (fr)	2005-09-15	Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
WO2007070432A3 (fr)	2007-11-29	Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci
WO2006124269A3 (fr)	2008-12-04	Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles
WO2005016111A3 (fr)	2006-05-04	Anticorps diriges vers l'hormone parathyroide et leurs utilisations
WO2006071441A3 (fr)	2007-02-22	Anticorps dirigés contre la gpnmb et leurs utilisations
WO2006055638A3 (fr)	2006-08-24	Anticorps monoclonaux entierement humains diriges contre l'il-13
WO2006039258A3 (fr)	2006-09-14	Anticorps diriges contre la parathormone
WO2008009960A3 (fr)	2008-07-10	Anticorps diriges contre la testosterone
WO2004050032A3 (fr)	2004-08-26	Anticorps contre les drogues toxicomagenes
EP2548583A3 (fr)	2013-02-27	Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
AR035581A1 (es)	2004-06-16	Anticuerpos para il-1beta humana
WO2007065037A3 (fr)	2008-10-23	Anticorps dirigés contre mmp-13 (collagénase-3) et leurs utilisations